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Abstract
Background: Current diagnosis and treatment of urinary bladder cancer (BC) has shown great progress with the utilization
of microarrays.
Purpose: Our goal was to identify common differentially expressed (DE) genes among clinically relevant subclasses of BC
using microarrays.
Methodology/Principal Findings: BC samples and controls, both experimental and publicly available datasets, were
analyzed by whole genome microarrays. We grouped the samples according to their histology and defined the DE genes in
each sample individually, as well as in each tumor group. A dual analysis strategy was followed. First, experimental samples
were analyzed and conclusions were formulated; and second, experimental sets were combined with publicly available
microarray datasets and were further analyzed in search of common DE genes. The experimental dataset identified 831
genes that were DE in all tumor samples, simultaneously. Moreover, 33 genes were up-regulated and 85 genes were down-
regulated in all 10 BC samples compared to the 5 normal tissues, simultaneously. Hierarchical clustering partitioned tumor
groups in accordance to their histology. K-means clustering of all genes and all samples, as well as clustering of tumor
groups, presented 49 clusters. K-means clustering of common DE genes in all samples revealed 24 clusters. Genes
manifested various differential patterns of expression, based on PCA. YY1 and NFkB were among the most common
transcription factors that regulated the expression of the identified DE genes. Chromosome 1 contained 32 DE genes,
followed by chromosomes 2 and 11, which contained 25 and 23 DE genes, respectively. Chromosome 21 had the least
number of DE genes. GO analysis revealed the prevalence of transport and binding genes in the common down-regulated
DE genes; the prevalence of RNA metabolism and processing genes in the up-regulated DE genes; as well as the prevalence
of genes responsible for cell communication and signal transduction in the DE genes that were down-regulated in T1-Grade
III tumors and up-regulated in T2/T3-Grade III tumors. Combination of samples from all microarray platforms revealed 17
common DE genes, (BMP4, CRYGD, DBH, GJB1, KRT83, MPZ, NHLH1, TACR3, ACTC1, MFAP4, SPARCL1, TAGLN, TPM2, CDC20,
LHCGR, TM9SF1 and HCCS) 4 of which participate in numerous pathways.
Conclusions/Significance: The identification of the common DE genes among BC samples of different histology can provide
further insight into the discovery of new putative markers.
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Introduction
Cancer of the urinary bladder (BC) is the fifth most common
cancer in men. The peak prevalence of the disease is among
patients 60–70 years of age. BC is curable if diagnosed during the
early stages of the disease. Tumors of the urinary bladder develop
via two distinct but somewhat overlapping pathways: the papillary
and non-papillary. Approximately 80% of BCs consist of
superficial exophytic papillary lesions that originate from urothe-
lial hyperplasia. These typically low-grade papillary tumors may
recur, but rarely invade the bladder wall or metastasize. The
remaining 15–20% of tumors represent high-grade solid non-
papillary BCs that arise from high-grade intraurothelial neoplasia.
These tumors aggressively invade the bladder wall and have a high
propensity for distant metastasis [1].
Parallel gene-expression monitoring is a powerful tool for
analyzing relationships among bladder tumors, discovering new
tumor subgroups, assigning tumors to pre-defined classes,
identifying co-regulated or tumor stage-specific genes and
predicting disease outcome [2,3,4,5,6,7,8]. To date, much effort
has been spent in order to identify genes that display differential
expression (DE) between various tumor types vs. other tissue
groups, such as phenotypically normal tissue. However, the
reported DE genes vary among different study groups, depending
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One intriguing issue that has not as yet been contemplated
involves possible data that can be gathered regarding genes that
are differentially expressed simultaneously in all study tumor cases.
In the present study, we performed cDNA microarray analysis,
comprising in-house experimental as well as publicly available
data, to analyze the gene expression profile of BC and to
determine the DE genes between cancer and healthy tissue. The
detection of DE genes was performed in each sample individually,
as well as in each tumor group, as defined by histological
examination and reported data. Data were clustered with different
algorithms, and functions of the known DE genes were further
defined by Gene Ontology. Furthermore, we searched not only for
differences among tumor types, but rather for similarities. The
reason for this approach was that, although different tumor types
are expected to have differences in their expression profiles even
between individuals with the same tumor subtype, we hypothe-
sized that tumors possess similar characteristics that may
eventually lead to knowledge of the etiologies of carcinogenesis.
In a significant work by Goldstein et al. an attempt to detect a
common cell of origin for prostate cancers was reported. They
implied that, despite the differences that tumor cells do share,
there is a possibility of a common origin [9]. In the same direction
we attempted to identify common gene expression profiles among
different tumor tissues. At this point we should mention that gene
expression, particularly from tumor biopsies, represents literally a
‘‘snap-shot’’ of the state-space of the otherwise dynamic behavior
of the disease. Yet, this ‘‘snap-shot’’ might be adequate in order to
obtain useful information on the dynamics of the system of study.
Particularly in the case of tumors, it is the only tool we have in
order to extract information at the ex vivo level.
The present data support the value of microarray-based gene
expression signatures as these identify clinically important cellular
properties.
Materials and Methods
Tumor Tissue Sampling and Surgical Procedure
Ten urinary bladder cancer specimens from patients with newly
diagnosed BCs undergoing transurethral bladder tumor resection
at the Department of Urology, ‘‘Asklipieio’’ General Hospital,
Athens, as well as five normal tissue samples, were acquired after
the amount of tissue necessary for routine pathology examination
had been removed. The patients studied were of advanced age
(73.9612.0 years). The majority (6/10, 60%) were smokers or
former-smokers, whereas four (40%) were characterized by some
level of occupational exposure to agents associated with BC
(paints, chemicals, etc.). All tumor specimens were classified and
graded by the same pathologist. Histological grading was
performed using both the 1973 World Health Organization
(WHO) and the 2004 WHO/International Society of Urologic
Pathology (ISUP) classifications [1]. Tumor stage was assessed
according to the 2002 American Joint Committee on Cancer
staging system [10]. Written informed consent was obtained from
all patients included in this study. The study protocol was
approved by the Ethics Committee of the University of Crete.
Eligibility criteria used were electively dissected primary BCs and
the availability of DNA from normal and tumor tissue for
biomolecular analyses. Exclusion criteria were a history of
previous neoplasms and chemotherapy or radiation therapy prior
to surgery.
Tissue samples were obtained at surgery from the tumor and the
following three grossly normal selected sites (cold cup biopsies):
posterior wall, trigone, and area adjacent to the tumor. Parts of the
dissected normal samples were sent for histopathological analysis.
Tumor and normal tissues were frozen immediately in liquid
nitrogen, transported and stored at 280uC until DNA extraction.
Patients with non-muscle-invasive BCs were followed up with
periodical cystoscopic examinations and intravesical treatment as
indicated. Patients with invasive BCs were offered radical
cystectomy with or without systemic chemotherapy.
Immunohistochemistry
Sections, 3 mm thick, of formalin-fixed, paraffin-embedded
tissue were cut and placed on slides coated with 3-aminopropyl-
triethoxysilone. Slides were dried at 56uC for 1 h before
immunohistochemical staining. Tissue sections were deparaffi-
nized in xylene before rehydration in graded alcohols, and
endogenous peroxidase activity was blocked by treatment with 3%
H2O2 at room temperature for 15 min. Antigen unmasking was
performed by 30 min of incubation at 80uC in 10 mM trisodium
citrate (pH 6.1). Immunostaining and revelation were performed
on a Dako automate. Slides were incubated at room temperature
with primary polyclonal goat antibodies against anti-ErbB2 (1:800;
Dako), cyclin D1 (1:100; SP4; Epitomics), monoclonal antibody
against anti-p53 (1:250; E26; Epitomics) and monoclonal antibody
against anti-Ki-67 (1:100; SP6; Epitomics). Epitopes of the
primary antibody were localized by immunoperoxidase technique
using the secondary antibody avidin-biotin complex and peroxi-
dase substrate kit (kit 5001, Dako), according to the manufacturer’s
protocol. The sections were then treated with Chromagen 30–30
diaminobenzidene tetrahydrochloride to identify sites of immuno-
precipitation by light microscopy. Finally, sections were washed,
counterstained with hematoxylin, and mounted under cover slips.
No specific staining was observed when the primary antibody was
omitted from the protocol (negative control). Specificity of the
immunostaining was additionally controlled by simultaneous
staining of breast cancer samples with known ErbB2, cyclin D1,
p53 and Ki67 expression patterns. An experienced pathologist
scored the staining intensity at four levels (negative, weak,
moderate and strong), considering both color intensity and
number of stained cells.
Microarray Experimentation and Inclusion of Publicly
available Microarray Datasets
Oligos microarray chips (,57 k genes) were obtained from GE
HealthCare (IL) and AppliedMicroarrays (MA) (former Amer-
sham Biosciences) (CodeLink 57 k Human Whole Genome)
[11,12,13]. Hybridization was performed with the CodeLink
RNA amplification and Labeling kit as described by the
manufacturer, utilizing the Cy5 fluorescent dye. Slides were
scanned with a microarray scanner (ScanArray 4000XL). Images
were generated with ScanArray microarray acquisition software
(GSI Lumonics, USA). cRNAs from three experimental setups
were used in single experiments with internal spikes as controls.
The experimental setups consisted of 10 urinary BC samples of
different histology (see Tissue Sampling and Surgical Procedure
section) and 5 control samples. The scanned images were further
processed with the CodeLink Expression Analysis Software v5.0
from Amersham Biosciences (presently GE Health Care Inc.). The
experimental setup was analyzed based on the reference-design as
described previously [14,15,16] as presented in Figure S1A. All
tumor samples were compared against the mean value of the
control samples. Raw microarray data are available at the GEO
microarray database. All microarray data are MIAME compliant.
In order to expand the number of BC samples under
investigation, we included the following publicly available
microarray datasets in our analysis: 1) GSE89 dataset (GDS183)
Differentially Expressed Genes in Bladder Cancer
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(GDS1479) [18], comprised of 60 samples (9 controls and 51 BC
samples); 3) GSE7476 dataset [19], composed of 12 samples (3
controls and 9 BC samples) and 4) GSE12630 dataset [20],
comprised of 19 BC samples. In total, our pooled microarray
analysis was composed of 17 control samples (n=5, for the
CodeLink platform; and n=12, for the remaining microarray
platforms) and 129 BC samples (n=10, for the CodeLink
platform; and n=119, for the remaining microarray platforms).
Public data were used in their available normalized form, since
background correction and normalization had already been
performed.
Microarray Data processing
Microarray Data Filtering and Background Correction of
the CodeLink Platform. Filtering is performed based on the
signal intensity and on the criterion of whether this signal is above a
certain level. In our analysis, filtering was performed using the
equation: SvBLz1:5:sBL, where S is the measured signal intensity,
BLis the local background measured and sBL is the standard deviation
of the local background. Signals with intensity lower than the above
measured, obtained a flag. Background correction was performed by
subtracting the median global background from the median local
background from the signal intensity.A threshold of2 wasset as cut-off,
meaning that spot intensity for at least one channel should be twice as
much as that of the background.
Microarray Data Normalization of the CodeLink
Platform. Microarray data were normalized by the default
procedure of the CodeLink software, i.e. spot intensities were divided
by the global median (global median normalization) [13]. Normalized
data were extracted, pre-processed and sorted with Microsoft Excel H.
For further data analysis the Matlab H (The Mathworks Inc.)
computing environment was used. Data were examined for their
distribution pattern for further choice of the statistical test method.
Microarray Data Cross-Normalization. Microarray data
were cross-normalized, using a quantile algorithm, in order to
account for the bias that was included due to experimentation,
different platforms and different sampling (Figure S2).
Normalization of cross-platform data has been previously
described [21,22,23] with very good correlations and consistency
between the CodeLink and Affymetrix platforms [24,25].
Creating a Common Gene List and BC Groups
In order to ensure that the results of our analysis were
comparable, we created a common gene list among all microarray
platforms. For this purpose, the NCBI Gene ID number was used
as a common reference. After comparing the DE genes among all
datasets, only those present in all platforms were selected for
further analysis. In total, this filtering approach yielded a gene set
of 11,837 unique records, simultaneously present in all microarray
platforms. Datasets were used as individual samples as well as in
tumor groups. The group distribution is presented in Table S1.
Microarray Data Statistics for the CodeLink Platform and
the Publicly available Microarray Datasets
In regards to the CodeLink platform, our approach consisted of
the following methodology. Each gene was tested for its significance
in differential expression using a z-test. Genes were considered to be
significantly differentially expressed if they obtained a p-val-
ue,0.05. Comparisons were made both among experiments as
well as within experiments. Set manipulationwas then used in order
to discover further subsets that would characterize, if possible, all
tumor samples. For further analyses we used the genes that were
differentially expressed among tumor samples.
Regarding the comparison among genes of all of the available
microarray datasets, we used the following methodology:
a) First, we searched for differences, comparing all control
samples (considered as one group), against all tumor samples
(considered as another group), using a two-tailed two-sample
T-test. Since these groups contained samples which varied in
ethnicity and tumor grade, we controlled all bias by
comparing them as unified groups.
b) Second, we separated samples into groups (11 groups in total)
(Table S1), and each group was compared against all control
samples, using a two-tailed two-sample T-test.
c) Third, we compared samples individually for significant genes
among each experiment, using a two-tailed z-test, which is
referred to as ‘‘intra-experimental’’. This type of comparison
had a particularity. Since expression of the genes was
compared to the mean of the gene expression within the
same experiment, the DE genes would signify the difference
that each tissue sample exhibited in comparison with the
normal tissues. This means that the common genes among
them would be those genes that are common to the tumor
tissue.
d) We compared samples individually for significant genes i.e.
gene ratios, among experimental setups, using a two-tailed z-
test, which we refer to as ‘‘inter-experimental’’. In other
words, we searched for genes that exhibited different
expression from one sample to the next but not against the
control samples. Interestingly, the significant genes derived
from these included genes that were not DE. In other words,
these genes were identified among those whose expression
remained the same across all samples.
In order to identify the differentially expressed genes, we used
two methods. Genes were considered to be significantly differen-
tially expressed if they obtained a p-value,0.05. Comparisons
were made both among experiments as well as within experiments.
Set manipulation was then used in order to discover further subsets
that would characterize, if possible, all tumor samples. For further
analyses we used the genes that were differentially expressed
among tumor samples, on a need-to-use basis. In the case where
sample groups were compared, the mean of each gene was taken
against the mean of all control samples. In the case of individual
comparisons of samples, gene ratios were calculated against the
mean of all control samples.
False Discovery Rate (FDR)
The False Discovery Rate was calculated as previously
described [26,27,28].
Clustering Analysis
Clustering analysis was performed with the k-means algorithm.
In total, 81 clusters of the complete dataset of the CodeLink
platform and 100 clusters for all available datasets, were formed
and DE genes were further classified using two-way (genes-against-
samples) average-linkage hierarchical clustering with Euclidian
distance [29]. Clustering analysis and chromosome mapping were
in part performed with Genesis 1.7.2 (Technische Universitaet-
Graz, Austria) using Pearson’s correlation (r) and Spearman’s rank
order correlation (r) [30,31,32].
TFBM Analysis
In order to identify the transcription factors driving the
observed changes in the gene expression, we investigated the
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tion Element Listening System Database (TELiS) (www.telis.ucla.
edu) [33]. The TRANSFAC transcription factor database was
used for the identification of gene transcription factor binding sites
[34].
Chromosome Mapping
Chromosome mapping appears to be a promising method for
identifying patterns among genes. The main idea reported initially
by Cohen et al. is to map genes on chromosomal regions and in this
way if correlations do exist they appear through the location of
genes on chromosomal regions, since consecutive genes are often
similarly expressed [30]. For chromosome mapping analysis, we
used the Gene Ontology Tree Machine, WebGestalt web-tool
(Vanderbilt University, The Netherlands, http://bioinfo.vander-
bilt.edu/gotm/) [35] and the Matlab H (The Mathworks Inc.)
computing environment.
Gene Ontology (GO) Analysis
Gene Ontology (GO) analysis was initially performed using the
eGOn online tool for Gene Ontology (The Norwegian University
of Science and Technology, Trondheim, Norway, http://www.
genetools.microarray.ntnu.no/egon/) in order to find missing gene
symbols [36]. WebGestalt web-tool (Vanderbilt University, The
Netherlands, http://bioinfo.vanderbilt.edu/gotm/) [35,37] was
used for gene function classifications. Relations of the differentially
expressed genes and the transcription factor binding motifs were
further investigated using the Pubgene Ontology Database (www.
pubgene.org). Gene definitions and functions were based on the
National Institute of Health databases (http://www.ncbi.nlm.nih.
gov/sites/entrez/).
GEO accession numbers
Array data were deposited at the Gene Expression Omnibus
(National Center for Biotechnology Information) with accession




Tumor samples were stained with antibodies for ErbB2, cyclin
D1, p53 and Ki-67. If present, anti-ErbB2 staining in tumor
samples is a membrane staining, diffuse in the urothelium
(Figure 1). All TCC samples (100%) showed moderate/strong
(++, +++) immunostaining, whereas no TCC sample showed no/
weak immunostaining (0, +). Thresholds for high labeling indices
were set for Ki-67 at $10% positive tumor nuclei and for p53 at
10 and 20%. T1/2-Grade III tumors exhibited the strongest
immunostaining (+++, .70%). T1-Grade I/II tumors showed
weak staining for anti-Ki-67 (40% and 7.5%, respectively),
whereas T1/2-Grade III tumors exhibited the strongest immuno-
staining (54%). Similarly, T1-Grade I/II tumors showed weak
staining for anti-p53 (10% and 35%, respectively), whereas T1/2-
Grade III tumors exhibited the strongest immunostaining (53%).
On the other hand, T1-Grade I/II tumors showed intense staining
for anti-Cyclin D1 (80% and 80%, respectively), whereas T1/2-
Grade III tumors exhibited weak immunostaining (31.8%).
CodeLink Platform Data Distribution and Analysis
Microarray data were investigated for their normal distribution
property. The normalized data followed a normal distribution as
presented in Figure S1B and S1C. Z-test statistics were applied
on the data, both on individual samples as well as on tumor
groups. In the case of tumor groups, genes that obtained a p-
value,0.05 were considered differentially expressed. In Figure
S3A–C the distribution of the p-values is presented. FDR was
calculated as previously reported [27,28]. FDR was calculated to
be 9.3% for a p-value,0.05 for tumors of the T1-Grade II group,
8.6% for p-value,0.05 for tumors of the T1-Grade III group and
11.03% for p-value,0.05 for tumors of the T2 and T3-Grade III
group (Figure S3D–F). The same procedure was followed for
each sample individually. Genes were plotted in box-plots in order
to examine the expression distributions in further detail. Box-plots
of tumor groups as well as those for individual samples are
depicted in Figure S4A and Figure S4B, respectively.
Analysis of Common Differentially Expressed Genes:
CodeLink Platform
In order to identify gene expression patterns in urinary BC, we
further analyzed our microarray data in such a way that common
patterns of expression among the different samples were identified.
We focused our analysis, not only on the differences between
tumor samples, but also on their similarities. It was not surprising
that such similarities did exist. Intersections of individual tumor
samples revealed 831 genes that were simultaneously differentially
expressed in all of the tumor samples (either up-, or down-
regulated). Of these DE genes, we identified 33 genes with
simultaneous increased expression and 85 genes with simultaneous
decreased expression in all BC samples, compared to normal
tissue.
Among the up-regulated genes, those presenting the highest fold
expression (mean6SD) were: hypoxia-inducible protein 2 (HIG2;
NM_013332.1) (2.7060.54); APC11 anaphase promoting com-
plex subunit 11 (ANAPC11; NM_001002245.1) (2.5060.60);
zo54e12s1 Stratagene pancreas (#937208) cDNA clone IM-
AGE:590734 39 similar to TR:G1022718 G1022718 NUCLEAR
RECEPTOR CO-REPRESSOR (NCOR1; AA156336.1)
(2.0161.13); UI-1-BB1p-atp-e-01-0-UIs1 NCI_CGAP_Pl6 cDNA
clone UI-1-BB1p-atp-e-01-0-UI 39, (BU754189; BU754189.1)
(1.8960.56). Similarly, the genes that exhibited the lowest fold
expression rates (mean6SD) were: tn52a12.x1 NCI_CGAP_
Kid11 cDNA clone IMAGE:2171998 39 similar to contains
PTR5.b2 MER22 repetitive element (AI565993; AI565993.1)
(23.1360.66); zx51b02r1 Soares_testis_NHT cDNA clone IM-
AGE:795723 59 (AA461577; AA461577.1) (22.7560.86); lacto-
transferrin (LTF) (ANKRD29; NM_173505.2) (22.2861.17);
HUMNK566 Human epidermal keratinocyte cDNA clone 566
(ODZ2; D29453.1) (22.1561.02); tumor necrosis factor
receptor superfamily, member 17 (TNFRSF17) (TNFRSF17;
NM_001192.2) (22.0760.73); and skeletal muscle LIM-protein
FHL1 mRNA (FHL1; U60115.1) (22.0660.87).
Regarding the three tumor groups (T1-Grade II, T1-Grade III
and T2/T3-Grade III), our analysis did not show a subset of genes
common to all groups. Therefore, we investigated the common
DE genes between pairs of tumor groups (Tables S2, S3, S4).
DE genes common to all individuals regardless of tumor group,
were further clustered using hierarchical clustering with Euclidean
distance. Groups of common genes in several combinations are
presented in Table S5.
Hierarchical Clustering with Euclidean Distance:
CodeLink Platform. We performed two-way average-linkage
hierarchical clustering with Euclidian distance for ,57 k genes. A
detailed view of the sample cluster dendrogram is displayed in
Figure 2. We partitioned the tumors into two main groups and
several subgroups based on the differential expression of their
genome. The first branch contained a T1-Grade II tumor and the
Differentially Expressed Genes in Bladder Cancer
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clustered into additional subgroups.
K-means clustering: CodeLink Platform. K-means
clustering algorithm is another way of classifying data in order
to find patterns of expression. Our analysis was organized as
follows:
i. k-means of all genes and of all samples. The result of k-means
clustering of all genes and all samples is presented in
Figure 3A. We clustered data in 49 clusters along with
their centroids (Figure 3B). For each cluster group there
were several genes that characterized the cluster i.e.
characterized the sample that the genes belonged to.
ii. k-means of common DE genes in all samples. The common
DE genes among all samples were furthered clustered
(Figure 4A and 4B).
iii. k-means of tumor groups. To conclude the analysis based on
k-means clustering the tumor groups were analyzed as
defined above. The results are presented in Figure 5A
and 5B for cluster and centroids, respectively. Clusters of
tumor groups revealed both differences as well as similarities
between the different groups. For example, certain gene
categories revealed constitutive down-regulation in one tumor
group vs. the group of higher stage/grade, whereas other
gene categories exhibited constitutive up-regulation between
the corresponding groups (clusters 11, 24, 27, 30, 33, 41, 46).
At the same time several clusters included genes that
remained unchanged between tumor groups (clusters 21,
26, 35, 37, 45, 47, 48).
Principal Component Analysis (PCA): CodeLink Platform
i. PCA of all genes in all samples. PCA analysis of our data was
further carried out in order to search for other potential
patterns among the genes. The initial analysis was
performed with genes that were commonly DE among all
samples. Calculated principal components were plotted
against each other in scatter plots as presented in
Figure 6. PCA analysis of the genes was performed in
order to find further patterns in the expression data. To
perform the present analysis with all genes and in all
samples, the initial step was to plot scatter plots of all
combinations of the principal components (Figure 6A, B).
The genes manifested several patterns as noted in the circled
areas in Figure 6B. Then, samples were examined for the
percentage of variance they attributed to the principal
components (Figure 6C, D). Finally, a biplot was
Figure 1. T2-Grade III tumors exhibited the strongest immunostaining for anti-cerbB2 (+++, .70%), anti-Ki67 (.70%) and anti-p53
(85%). On the other hand, T1-Grade II tumors showed intense staining for anti-Cyclin D1 (80%), whereas T1-Grade III tumors exhibited weak
immunostaining. Representative H&E slides denote the histology of T1-Grade II, T1-Grade III and T2-Grade III tumors.
doi:10.1371/journal.pone.0018135.g001
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respect to total gene expression (Figure 6E). As presented in
the circled areas in Figure 6E, samples were grouped into
two main categories: samples 22A (T2/T3-Grade III), 27A
(T1-Grade III) and 29A (T2/T3-Grade III) on one hand,
and the rest of the samples were grouped together. In order
to further resolve for differences based on PCA analysis we
compared gene expression as follows.
ii. PCA of common DE genes in all samples. PCA analysis of the
common DE genes is presented in Figure 7. Grouping of the
samples based on principal components showed different
classifications. Tumor samples 2A, 3A and 4A were grouped
distinctively as per the first three principal components
(Figure 7E). These three samples were grouped together
when the complete data set was considered. Resolving this
result with the common DE genes showed a difference
between tumor groups. Similarly, several different groupings
were obtained by PCA analysis of the common DE genes
among all samples, such as among tumor samples 22A, 10A,
samples 2A, 4A, 16A that formed a separate group and
samples 3A, 17A, 26A, 27A, 29A that formed another one
(Figure 7F). Similarly, plotting of the components grouped
samples 3A and 16A, as well as samples 2A, 4A and 10A in a
separate group.
iii. PCA of the tumor groups. PCA analysis of tumor groups
showed a distinct separation among the three groups (T1-
Grade II, T1-Grade III and T2/T3-Grade III) (Figure 8).
Transcription Factor Binding Motif (TFBM) Analysis:
CodeLink Platform. One of the main parts of our data analysis
included the determination of the over-represented TFBMs in the
promoters of the DE genes. This provides inferences about which
transcription factors are active. We searched for TFBMs in all
combinations of gene expression as presented in Table 1 and the
results are presented in Table S4. Attention was focused on two
transcription factors, YY1 and NFkB. YY1 appeared to commonly
regulate the expression of down-regulated genes in T1-Grade II
and simultaneously in T1-Grade III. NFkB, on the other hand,
appeared to regulate common DE genes between tumors of T1-
Grade III and those of T2/T3-Grade III. In particular, it
appeared that the p65 subunit of NFkB was a common
denominator for the two tumor groups.
Chromosome Mapping: CodeLink Platform. Chromosome
distributions of the expressed data werealso carried out in an attempt
to search for more patterns in gene expression with respect to
chromosome gene expression distribution. Chromosome distribution
of the common DE genes is presented in Figure 9.
Common DE genes among all BC samples showed peaks of
gene expression in chromosomes 1, 2 and 11 (Figure 9A).
Chromosome 1 contained 32 (10.2%) DE genes, followed by
chromosomes 2 and 11, which contained 25 (7.9%) and 23 (7.3%)
DE genes, respectively. Chromosome 21 had the least number of
DE genes (n=3; 0.9%).The down-regulated genes exhibited peaks
of gene expression in chromosomes 1 (5/36; 13.8%), 3 (4/36;
11.1%) and 11 (4/36; 11.1%). Chromosomes 4, 5, 6, 14, 15, 21, 22
and Y, did not present any down-regulated gene (Figure 9B). The
up-regulated genes showed peaks in chromosomes 1 (2/14; 14.2%)
and 7 (2/14; 14.2%); whereas chromosomes 1, 5, 7, 9, 10, 15, 16,
18, 19 and 22 contained 1 up-regulated gene (1/14; 7%)
(Figure 9C). In concordance, gene distribution manifested a
peak in chromosome 19 for common DE genes between groups
T1-Grade II and T2/T3-Grade III (Figure 9D), while chromo-
some X appeared to express most genes between down-regulated
genes in group T1-Grade III and simultaneously in up-regulated
genes in group T2/T3-Grade III (Figure 9E).
Furthermore, we examined the expression of all genes as
distributed on each chromosome. This was performed by
evaluating the mean gene expression for up- and down-regulated
genes separately, since up-regulated genes are those that are active
in tumor samples as compared to control and down-regulated
genes are those that are active in control samples as compared to
tumor samples. Hence, for tumor samples the maximum activity
occurred on chromosomes 9, 22, X and for control samples on
chromosomes 10, 19 and X.
A chromosomal correlation analysis was also carried out, as
previously described by Cohen et al. [30]. We used chromosomal
correlation maps to reveal common expression patterns among
genes (Figure 9G–L). In particular, we searched for common
chromosomal expression among all chromosomes. Those mani-
festing certain correlation patterns included chromosomes 1
(Figure 9G), 4 (Figure 9H), 8 (Figure 9I), 13 (Figure 9J), 21
(Figure 9K) and chromosome 22 (Figure 9L), with chromosome
4 manifesting the most prevalent correlation pattern (Figure 9H).
The fewest genes were mapped on chromosomes 13 and 21, which
indicated that gene activity does not correlate with the number of
genes active on a chromosome.
Functional Categories of differentially expressed genes
and Gene Ontology Annotation: CodeLink Platform. Gene
definitions were used according to the NCBI (http://www.ncbi.
nlm.nih.gov). Each gene can belong to more than one category.
Categories of known genes were Biological Process (30.94%), Cellular
Component (34.66%) and Molecular Function (33.76%). Furthermore,
biological process was divided as presented in Figure 10.W e
searched further into the biological process category, and the
results of the functional annotation are presented in Figure 10B–
D. From the immense number of functions of the DE genes, five
categories were outlined: cell death, cell growth, metabolism,
development and RNA processing. Genes related to cell death
included MALT1, RHOT2, SON, CECR2, F2, PDE1B, PAK1,
PLA2G6, CRADD, DNM1L, PDCD7, PUF60, ADAMTSL4, PERP,
MARK4, DIDO1 and BCL2L1. Genes related to cell growth
Figure 2. Hierarchical clustering with Euclidean distance
revealed groups of genes of common and differential
expression.
doi:10.1371/journal.pone.0018135.g002
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clusters 1, 3, 4, 5, etc.
doi:10.1371/journal.pone.0018135.g003
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distinction can be made between individual samples.
doi:10.1371/journal.pone.0018135.g004
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18135Figure 5. K-means clusters (A) and respective centroids (B) of tumor groups: T1-Grade II, T1-Grade III and T2/T3-Grade III.
doi:10.1371/journal.pone.0018135.g005
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related to embryonic development included among others
ADAM10, TNFRSF17, MYF5, CAP2 and NDRG3. Genes related
to metabolism included among others ATP2B4, GOLGA2L1,
MMP24, RPLP1, APOC2. Finally, among the RNA processing
and transcription regulation genes were ZNF132, ZNF135 MYF5,
PPARG, ATOH8 and others.
Cell death-related genes had no other subcategories. Cell
growth-related genes were further divided into negative and
positive regulation of cell growth (11.1% respectively), regula-
Figure 6. PCA analysis of genes was performed in order to find further patterns in the expression data. The first step to perform the
present analysis with all genes and in all samples was to plot scatter plots of all combinations of principal components (A, B). Genes manifested
several patterns as it is seen in the circled areas in B. Then, samples were examined for the percentage of variance they attributed to the principal
components (C, D). Finally, a biplot was drawn on order to examine sample classification with respect total gene expression (E). As it is presented in
the circled areas in E, samples were grouped into two main categories: samples 22A (pT2- pT3-Grade III), 27A (pT1-Grade III) and 29A (pT2- pT3-Grade
III).
doi:10.1371/journal.pone.0018135.g006
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PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18135tion of growth (33.33%) and cell growth per se (44.4%).
Metabolism-related genes were subdivided into catabolic
processes (4.91%), regulation of metabolic processes (9.31%),
nitrogen compound metabolic process (10.49%), biosynthetic
processes (10.66%), macromolecule metabolic processes
(17.94%), cellular metabolic processes (20.14%) and primary
metabolic processes (21.15%). Finally, developmental genes
were further divided into embryonic development (2.67%),
negative regulation of embryonic development (2.67%), positive
regulation of developmental processes (9.33%), regulation of
developmental processes (9.33%), anatomical structure morpho-
genesis (10%), cellular developmental processes (5.33%), ana-
tomical structure development (21.33%) and multicellular
organismal development (26%).
In order to gain more insight into gene functions GO analysis
was performed on the groups of commonly regulated genes as they
were described in Table 1. Dendrograms were used with the
hypergeometric test for determining statistical significance, as
described by Zhang et al. [35,37] for genes that were differentially
expressed between tumor samples and tumor groups, respectively.
Figure 10E–L documents the significant (p,0.05) gene annota-
tions that were found with Gene Ontology analysis. Attention
should be focused on two categories: In the common down-
regulated genes, the prevalence of transport and binding genes was
observed (Figure 10E). At the same time, the prevalence of RNA
metabolism and processing genes among the up-regulated genes
was significant (Figure 10G). Regarding the DE genes that were
down-regulated in tumors of T1-Grade III and were simulta-
neously up-regulated in tumors of T2/T3-Grade III, genes were
identified whose significant functions were cell-cell communication
and signal transduction (Figure 10J).
Comparison between two groups: all tumor samples
versus all control samples
A two-sample T-test was performed in order to identify DE
genes between those two groups. This analysis revealed 434 DE
genes. Hierarchical clustering (HCL) showed a clear distinction
among tumor samples (Figure 11). It clustered groups of genes
according to their tumor class. k-means clustering on this gene
subset was also carried out in order to detect commonly expressed
genes (Figure 12). From the cluster analysis we were able to
identify three groups of genes that were down-regulated in all
samples: Clusters 79, 81, 82 represent genes that were down-
regulated in the majority of genes. Specifically, these genes were
BMP4, CRYGD, DBH, GJB1, KRT83, MPZ, NHLH1, TACR3 in
cluster 79; ACTC1, MFAP4, SPARCL1, TAGLN in cluster 81; and
TPM2 in cluster 82. No gene was simultaneously up-regulated in
all of the samples.
CDC20: A common marker among tumor
groups. Tumor samples were separated into groups as
described in Table S1. Each group was compared against all
control samples and identified DE genes. The goal of this analysis
was to identify genes that were simultaneously DE in all tumor
groups. Indeed, we identified one known gene, the cell division
cycle 20 homolog (Gene ID: 991) or CDC20. CDC20 is a cell cycle
regulator among other functions, and, to date, there are no other
reports linking it to bladder cancer. CDC20 appeared to be
commonly differentially expressed in all tumor groups, except for
the Ta-grade3 group. Its expression levels are depicted in
Figure 13. CDC20 appeared to be over-expressed in the
majority of the tumor samples.
LHCGR is the most common DE gene among the
individual tumor samples: The Intra-experimental
Case. We compared genes in tumor samples individually, as
ratios, within the same experiment. Our analysis showed that
LHCGR was the most common DE gene found among the tumor
samples. In particular, LHCGR was differentially expressed in 108/
129 (83.7%) samples (Figure 14A). We also outlined the genes
that appeared to be differentially expressed in at least one BC
sample. In this group both HCL and k-means clustering were
performed (Figure 14). However, no further groups of genes with
common expression were revealed.
Common genes that were not differentially expressed:
The Inter-experimental case. Similarly, as in the case of
Intra-experimental comparisons, we searched for DE genes among
all tumor samples. However, no surprising results were obtained
since DE genes were expected to be encountered across such a
wide range of samples. Yet another group of genes triggered our
interest: those genes that were not DE across all tumor samples.
Their importance lies in the fact that they were similar in all
bladder cancer types, regardless of population, sampling method
or microarray platform and experimentation procedure. The
results are presented in Figure 15. However, they did not give
groups of similar expression.
Combining the two cases: Intra-experimental vs. Inter-
experimental. Since the analysis of individual samples did not
provide distinct gene groups, we searched for genes that were: (a)
unchanged in the intra-experimental, and DE in the inter-
experimental comparisons; and (b) unchanged in the inter-
experimental and DE in the intra-experimental comparisons. For
case (a), two genes fulfilled both requirements: HCCS (holocytochrome
c synthase; ID: 3052) and TM9SF1 (transmembrane 9 superfamily
member 1; ID: 10548) (Figure 16). Moreover, the comparison for
case (b) revealed LHCGR (luteinizing hormone/choriogonadotropin
receptor; ID: 3973), a gene that also appeared to be the most common
DE gene among the tumor samples.
Transcription Factor Binding Motif (TFBM) Analysis:
Cross-Platform Comparisons. Across the commonly
expressed genes that were identified in the majority of tumor
samples, TFBM analysis was performed in order to identify
transcription factors (TFs) which might affect expression of the
genes. The TFs predicted by our analysis are summarized in
Table 2. Unexpectedly, the glucocorticoid receptor (GR) was
predicted as one of the TFs in the common gene set. In order to
find which gene was most commonly represented among the TFs,
we plotted the incidence of each gene as a function of the times of
appearance within the predicted TFs (Figure 17). The gene BMP4
(bone morphogenetic protein 4; ID: 652) had the most binding
sites for the predicted TFs. To our surprise, CDC20 and LHCGR
were not represented in the TFBM analysis.
Chromosome Mapping: Cross-Platform Comparisons.
Chromosome mapping was performed with the genes that were
identified as common, among all BC samples (Figure 18). In BC,
most chromosomes had inactivated (down-regulated) genes, versus
the control samples. However, two genes were an exception:
CDC20 (in chromosome 1) and HCCS (in chromosome X).
Pathway analysis of common genes. Considering that the
genes which were identified as being common play an important
role in bladder cancer, we further attempted to isolate those genes
Figure 7. PCA analysis of common DE genes. Scatter plots of principal components (A, B) are presented. Sample 2A attributes the observed
variance (D). Plotting of the components showed different groupings among samples as it is shown in E, F, G.
doi:10.1371/journal.pone.0018135.g007
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we hypothesized that the genes which would fulfill such a
requirement should participate in more than one familiar
pathways. Indeed, we encountered four genes that participated
in eight different pathways, as depicted in Table 3.
Functional Categories of differentially expressed genes
and Gene Ontology Annotation: Cross-Platform
Comparisons. Finally, GO terms in which the genes
participated were analyzed (Figure 19). Three main functions
were outlined: a) circulatory system regulation, b) reproductive
Figure 8. PCA analysis of tumor groups. Scatter plots of principal components are presented (A, B), observed variance (C, D) and biplot
classification of tumor groups with respect to principal components (E).
doi:10.1371/journal.pone.0018135.g008
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This enrichment showed that the predicted gene set has more than
a dual role.
Discussion
Several studies have focused on the expression profiling of
urinary bladder cancer using microarrays. The purpose of these
studies was the classification of bladder cancer, the definition of
biological phenotypes, the identification of gene expression
patterns in superficial and invasive human bladder cancer, the
identification of superficial, muscle-invasive, and metastasizing
transitional cell carcinoma of the bladder. [17,18,38,39,
40,41,42,43,44,45]. In the present study, the experimental
pathologic cases were carefully selected in order to obtain at least
one pair from each tumor group: T1-Grade II, T1-Grade III and
T2/T3-Grade III. Furthermore, in our pooled microarray
analysis, a wide range of data from publicly available microarray
datasets was included, increasing the number of specimens under
investigation, to 129 BC samples and 17 controls in total.
To date, the main approach in microarray analysis has been the
discovery of differences between pathogenic samples. The purpose
of these studies was to detect patterns that discriminate between
further subcategories of pathogenic samples, such as tumors.
However, the fact that, instead of bearing differences, various
tumors can also possess many similarities explained by their
common origin or by a common general mechanism of
tumorigenesis, has been neglected. Since tumors do possess similar
characteristics regardless of the tumor type, it would be reasonable
to assume that such common phenotypical manifestations would
be reflected from genomic i.e. transcriptional similarities. There-
fore, we focused our analysis, not only on the differences between
tumor samples, but also on their similarities. We focused on the
genes that simultaneously exhibited differential expression (either
up- or down-regulation) among the different subclasses of BC,
compared to the normal tissue.
Therefore, instead of searching for classification patterns
between tumor samples based on gene expression profiles we
used a reverse engineering approach in order to search for
common patterns among different tumor samples. Since there are
expected differences between even similar samples, simply due to
the diversity that characterize biological systems, the chances of
finding common mechanisms are scarce. However, one could
argue that even if similarities are found, these may be attributed to
the fact that, from a huge gene pool, several similarly expressed
genes are expected to exist. Yet, if this process is random, then
similarities should include genes or functions that do not provide
any meaning with regards to the tumor/samples under study. In
other words, if we detect common genes with similar expression
among different, unconnected samples, this implies that several
Table 1. Transcription binding motif analysis of common DE genes and conditions between DE genes.
Common Gene Conditions TFBMs
Common DEs up-regulated among all
samples (p,0.002, FDR,40%)
V$ELK1_01 V$NRF2_01 V$SRF_Q6 V$E2_Q6
Common DEs down-regulated among all
samples (p,0.01, FDR,37.5%)
V$ARP1_01 V$AHRARNT_01 V$AP2_Q6 V$VMAF_01 V$ISRE_01 V$SP1_01 V$CDXA_01
Common DEs among pT1-Grade II
and pT1-Grade III (p,0.002, FDR,30%)
V$AP4_01 V$RORA2_01 V$EGR1_01 V$MZF1_01
Common DEs among pT1-Grade II
and pT2-pT3 Grade III (p,0.0002,
FDR,10%)
V$AHRARNT_01 V$EVI1_05 V$OCT1_03 V$HEN1_02 V$CAP_01
Common DEs among pT1-Grade III








Common DEs up-regulated in
pT1-Grade II and down-regulated
in pT1-Grade III
Non significant
Common DEs up-regulated in
pT1-Grade II and down-regulated
in pT2-pT3Grade III (p=0.0002,
FDR,40%)
V$VJUN_01
Common DEs up-regulated in
pT1-Grade III and down-regulated
in pT2-pT3Grade III (p,0.0002,
FDR,20%)
V$E2F_02 V$CREBP1_01 V$IK3_01
Common DEs down-regulated in
pT1-Grade II and up-regulated in
pT1-Grade III (p,0.0005, FDR,20%)
V$YY1_02 (p=10
27)V $AP4_01 V$E2F_02 V$ELK1_01
Common DEs down-regulated in
pT1-Grade II and up-regulated in
pT2-pT3Grade III
Non significant
Common DEs down-regulated in
pT1-Grade III and up-regulated in
pT2-pT3Grade III (p,0.0002, FDR,40%)
V$EGR1_01 V$EGR2_01
Attention is drawn to two very important transcription factors YY1 and NFkB. It appeared that down-regulated genes in T1-Grade II and up-regulated in T1-Grade III are
commonly regulated by YY1. Also, common DE genes between T1-Grade III and T2- pT3-Grade III appear to have transcription factor NFkB as a common denominator.
doi:10.1371/journal.pone.0018135.t001
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to include population and platform bias, we used all the available
control samples from all the microarray platforms that we studied.
Goldstein et al. and Hirsch et al. [9,46], investigated common
signatures for BC and cancer/lipid metabolism. These studies
suggest that biological systems on their way to disease follow
similar paths. Similarly, our approach aimed to identify similar
patterns among groups of different BC types.
Figure 9. Chromosome distribution of common differentially expressed genes. Common genes between all samples (A) showed peaks of
gene expression in chromosome 1, 11 and 19. Down-regulated genes (B) showed peaks of gene expression in chromosome 1 and 11. Up-regulated
genes (C) showed a peak in chromosomes 1 and 7. In concordance gene expression manifested a peak in chromosome 19 for common DE genes
between groups pT1-Grade II (group I) and pT2- pT3-Grade III (group III) (D), while chromosome X appeared to express most of genes between down-
regulated genes in group pT1-Grade III (group II) and simultaneously in up-regulated genes in group pT2- pT3-Grade III (group III) (E). The median
expression of all samples with respect to chromosomes is presented in (F) (numbers above and below bars indicate the chromosome). It appeared
that the most active chromosome is chromosome 9 for all tumor samples while controls manifest maximum median activity at chromosome 10 and
X. Correlation maps for all chromosomes has revealed some patterns within chromosomes 1 (G), 4 (H), 8 (I), 13 (J), 21 (K), 22 (L). Especially on
chromosome 4 it appeared that there is both negative as well as positive co-expression for the majority of the tumor samples.
doi:10.1371/journal.pone.0018135.g009
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The CodeLink Case. We initially determined gene groups
among the BC samples. This approach outlined differences
between samples. We identified 831 genes that were
differentially expressed in all 10 tumor samples simultaneously.
On the other hand, k-means clustering outlined several groups
with differential expression, such as clusters 3, 4, 5, 10, 12, 14 in
Figure 3B. When clustering for DE genes using only the k-means
algorithm, no clear distinction were detected among individual
samples, meaning that there were no clear differences among
samples. Furthermore, we investigated the presence of common
profiles, searching for simultaneously common up- and down-
regulated genes, among all tumor samples. Thirty-three genes
were up-regulated and 85 genes were down-regulated in all 10 BC
samples vs. the 5 normal tissues, simultaneously. The first finding
from classification analysis was that normal urothelium,
superficial, and muscle-invasive bladder cancers, showed distinct
gene expression profiles, as revealed by hierarchical clustering and
principal component analyses (Figure 8E). Yet, PCA analysis
indicated two main groups of expression profiles in all samples
Figure 10. Thirty-one percent (30.94%) of genes were attributed to Biological Process. Within biological processes (A) genes for growth
(B), metabolism (C) and development (D) were selected. Dendrograms (DAG trees) of Gene Ontology analysis of known differentially expressed genes
in all combinations as they are presented in Table S5 was performed. Interestingly, common up-regulated genes were attributed to RNA processing
and metabolism (G). The results include those combinations that have manifested significant function annotations at the p,0.05 level.
doi:10.1371/journal.pone.0018135.g010
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other hand, when PCA analysis was carried out for the DE genes,
only the samples were grouped into additional clusters
(Figure 7E–G). K-means clustering of all genes and all samples,
as well as clustering of tumor groups, revealed 49 clusters.
Moreover, k-means clustering of common DE genes in all samples
revealed 24 clusters.
We did not identify any genes that were commonly DE in all
tumor groups, simultaneously. Yet, we identified such genes in
tumor group pairs. Thirty-eight common DE genes were identified
between tumor groups T1-Grade II and T1-Grade III; 44 DE
genes were identified between groups T1-Grade II and T2/T3-
Grade III; and 33 DE genes were identified between groups T1-
Grade III and T2/T3-Grade III. The DE genes were also
analyzed in 6 different combinations between paired tumor
groups, i.e. all possible combinations of DE genes that were up-
regulated in one tumor group, and down-regulated in the other
(Table S5).
Cross-Platform Comparisons. The cross-platform analysis
after the inclusion of a larger microarray dataset, provided us with
an additional view of our concept. The number of common DE
genes was now confined to a smaller group of genes. In total, 17
genes appeared to be commonly expressed among all BC samples:
BMP4, CRYGD, DBH, GJB1, KRT83, MPZ, NHLH1, TACR3,
ACTC1, MFAP4, SPARCL1, TAGLN, TPM2, CDC20, LHCGR,
TM9SF1 and HCCS.
In regards to BMP4, there is only one previous report linking it
to bladder cancer, which suggests that its expression plays a
growth inhibitory role [47]. To date, there is no publication
indicating a connection among CRYGD, GJB1, KRT83, MPZ,
NHLH1, TACR3, ACTC1, MFAP4, SPARCL1, TAGLN, TPM2,
LHCGR, TM9SF1 and bladder cancer. Future investigation needs
to confirm the implication of these genes in urinary bladder
cancer. Cluster analysis revealed a common group of genes when
all controls and all BC samples were compared as two separate
groups. For the majority of the genes, there are no known reports
Figure 11. Hierarchical clustering (HCL) of between all control and all tumor samples, both considered as two separate groups. HCL
made distinctions between the different platforms, indicating that the DE genes were adequate to do such a classification. Hence, similarities from
this group would be expected to be due to the tissues per se.
doi:10.1371/journal.pone.0018135.g011
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doi:10.1371/journal.pone.0018135.g012
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PLoS ONE | www.plosone.org 18 April 2011 | Volume 6 | Issue 4 | e18135Figure 13. CDC20 expression across all samples. Apart from 9 samples, the gene appeared to be up-regulated in the rest 120 samples.
doi:10.1371/journal.pone.0018135.g013
Figure 14. LHCGR expression (A) and HCL of differentially expressed genes analyzed with one-sample z-test (B). (C) K-means clustering
of DE genes in Intra-experimental comparison. (D) centroids.
doi:10.1371/journal.pone.0018135.g014
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doi:10.1371/journal.pone.0018135.g015
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regulated CDC20, Kidokoro et al. recently mentioned that it has
potential therapeutic properties [48].
TFBMs
The CodeLink Case. Regarding TFBM analysis, Yin Yang 1
(YY1) and NFkB were among the most common transcription
factors regulating the expression of the identified DE genes. The
transcription factor (TF) YY1 commonly regulated the expression
of the down-regulated genes in T1-Grade II and simultaneously in
T1-Grade III. YY1 has been identified to target a plethora of
potential target genes, the products of which are important for
proliferation and differentiation, and has therefore been proposed
as an important prognostic marker for several human tumors
[49,50,51,52,53]. The mechanisms of YY1 action are related to its
ability to initiate, activate, or repress transcription depending on
the context in which it binds. YY1 over-expression has been
reported to affect the clinical behavior of several cancer types
Figure 16. HCCS and TM9SF1 were simultaneously unchanged in the intra-experimental and differentially expressed in the inter-
experimental comparisons. Expression profiles of HCCS (A) and TM9SF1 (B).
doi:10.1371/journal.pone.0018135.g016
Table 2. Predicted transcription factors (TFs) for 14 out of 17 genes commonly regulated in bladder cancer samples.
TFBM Inc. Gene IDs and Names
_WTGAAAT_UNKNOWN 4 8404 1421 4807 6870 SPARCL1 CRYGD NHLH1 TACR3
_CCAWWNAAGG_V$SRF_Q4 2 7169 6876 TPM2 TAGLN
_V$STAT3_02 2 652 10548 BMP4 TM9SF1
_RNGTGGGC_UNKNOWN 3 2705 652 4359 GJB1 BMP4 MPZ
_V$HMEF2_Q6 2 652 7169 BMP4 TPM2
_V$SRF_Q4 2 7169 6876 TPM2 TAGLN
_V$SMAD_Q6 2 652 6876 BMP4 TAGLN
_V$HEN1_01 2 652 4239 BMP4 MFAP4
_V$SRF_Q6 2 7169 6876 TPM2 TAGLN
_TTGTTT_V$FOXO4_01 4 8404 652 3052 4359 SPARCL1 BMP4 HCCS MPZ
_V$ZIC3_01 2 2705 4807 GJB1 NHLH1
_V$TTF1_Q6 2 652 7169 BMP4 TPM2
_V$GR_Q6_01 2 4359 4807 MPZ NHLH1
_V$HEN1_02 2 652 4239 BMP4 MFAP4
_V$ZIC1_01 2 2705 7169 GJB1 TPM2
_V$SRF_Q5_01 2 7169 6876 TPM2 TAGLN
_V$CEBPB_02 2 1621 4807 DBH NHLH1
_V$POU1F1_Q6 2 652 4807 BMP4 NHLH1
_SCGGAAGY_V$ELK1_02 3 2705 10548 3052 GJB1 TM9SF1 HCCS
_CAGGTG_V$E12_Q6 4 2705 652 4239 4807 GJB1 BMP4 MFAP4 NHLH1
_YNGTTNNNATT_UNKNOWN 2 652 7169 BMP4 TPM2
_WGGAATGY_V$TEF1_Q6 2 652 4359 BMP4 MPZ
doi:10.1371/journal.pone.0018135.t002
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been suggested, either through over- or under-expression,
depending on the tumor type. In bladder cancer, significant
differences have been detected between superficial TCC with
carcinoma in situ, and normal specimens, as well as between
muscle-invasive carcinoma and normal tissue [56].
Figure 18. Average gene expression with respect to their corresponding chromosomes.
doi:10.1371/journal.pone.0018135.g018
Figure 17. Incidence of genes among predicted transcription factors. The most prevalent gene was BMP4.
doi:10.1371/journal.pone.0018135.g017
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genes between tumors of T1-Grade III and those of T2/T3-Grade
III. In particular, the p65 subunit of NFkB was a common
denominator for the two tumor groups. Zhong et al. demonstrated
that transcriptionally inactive nuclear NFkB in resting cells
consists of homodimers of either p65 or p50 complexed with the
histone deacetylase HDAC1 [57]. Only p50-HDAC1 complexes
bound to DNA and suppressed NFkB-dependent gene expression
in unstimulated cells. Appropriate stimulation caused nuclear
localization of NFkB complexes containing phosphorylated p65
that associated with CBP and displaced the p50-HDAC1
complexes. These results demonstrated that phosphorylation of
p65 determines whether it associates with either CBP or HDAC1,
ensuring that only p65 entering the nucleus from cytoplasmic
NFkB -IKB complexes can activate transcription. The inhibitory
protein, NFKBIA, sequesters the transcription factor, NFkB, as an
inactive complex in the cytoplasm.
Cross-Platform Comparisons. BMP4 appeared to be the
gene with the most predicted transcription factor binding sites.
Also, when we examined the CodeLink platforms individually,
NF-kB was identified as a TF with a putative role in gene
regulation. Moreover, in the cross-platform comparisons we
identified the GR as a significantly implicated transcription
factor. Interestingly, both GR and NF-kB are two TFs that are
in interplay, at least in inflammation. The role of GR is already
known in hematologic malignancies. The role of NF-kB has also
been mentioned in drug resistance of neoplasias. However, their
role in BC is still unknown. Their appearance in the present
analysis, indicates a putative implication. GR has previously been
mentioned to participate in the oncogenesis of bladder cancer
[58]. Yet, it is still unclear whether the GR plays a role in BC.
Another TF predicted by our analysis was STAT3, previously
mentioned to be expressed in BC initiating cells [59].
Chromosome Mapping
The CodeLink Case. Chromosome mapping may be proven
to be a useful tool in the detection of gene expression patterns.
One-way ANOVA test showed significant differences between
samples 4A and 29A in up-regulated genes, as far as chromosome
gene expression is concerned (p,0.05)( Figure 20A), while no
differences were observed between down-regulated genes
(Figure 20B). The mean gene expression showed a maximum
on chromosome 9 (Figure 9F). This was interesting since the
relations between chromosome 9 and BC have been previously
reported [60,61]. Chromosome 9 has been reported to undergo
deletion of its long arm. Although, chromosome 1 manifested a
peak in gene number distribution (Figure 9A), gene expression
did not correlate with genes. Moreover, on chromosome 9, three
genes belonged to the commonly expressed genes. These were
LRRC8A (commonly down-regulated), C9orf103 and PTPDC1
(commonly up-regulated). There are no reports for these three
genes in regards to their relationship to BC. Our attention was
drawn to chromosome X, which is generally known to possess
active genes in cancer cells that are silenced in somatic cells. In
chromosome X, the gene FHL1 belonged to the commonly down-
regulated genes. Notably, it was recently reported that this gene is
hypermethylated and contributes to the invasion and migration of
BC [62]. Its expression among all samples, irrespective of the
tumor type, makes it an attractive target for further investigation as
a marker for tumor cell migration and invasion.
In order to gain further insight on gene expression with respect to
correlations between BC samples, we constructed correlation maps
as previously reported [30]. We searched for patterns among all
chromosomes. Yet, the most interesting pattern was manifested in
chromosome 4 which showed the greatest number of positive and
negative regulation between samples (Figure 9H). In chromosome
4, six genes were mapped: TACR3, RNF150, ANXA10, CENTD1,
EXOC1 and GRSF1. Interestingly, GRSF1 is a gene that is involved
in RNA binding and also stimulation of translation of viral mRNAs
in vitro. This gene was over-expressed in all samples except for case
29A, which is probably explained by the fact that all patients
received BCG treatment. From these genes, none belonged to a
common gene expression group, which makes the finding of
correlated expression stronger. In particular, samples 4A, 10A, 16A
and 17A showed positive correlation while 2A and 3A manifested
negative regulation with samples 4A, 10A, 16A, 17A and 27A.
The gene TACR3 belongs to a family of genes that function as
receptors for tachykinins. There are no reports on the role of
TACR3 in BC. Also, RNF150 a ring finger protein, has not been
previously reported regarding its relationship to BC. Similarly,
ANXA10, a gene that encodes a member of the annexin family is
reported for the first time to be correlated with bladder cancer.
Members of this family play a role in cell growth and signal
transduction. Likewise, the gene CENTD1 which contains a RAS-
associating homology domain has no previous reports regarding its
relationship to BC.
Table 3. Pathway participation of common genes in bladder cancer.
Pathway Genes Average expression
KEGG Cardiac muscle contraction 70 7169 ACTC1 TPM2 p,0.01 22.8730277 22.9625465
Dilated cardiomyopathy 70 7169 ACTC1 TPM2 p,0.01 22.8730277 22.9625465
Hypertrophic cardiomyopathy
(HCM)
70 7169 ACTC1 TPM2 p,0.01 22.8730277 22.9625465
Calcium signaling pathway 3973 6870 LHCGR TACR3 p,0.01 24.7375153 21.0159812
Neuroactive ligand-receptor
interaction
3973 6870 LHCGR TACR3 p,0.01 24.7375153 21.0159812
Pathway Commons Signaling by GPCR 3973 6870 LHCGR TACR3 p,0.01 24.7375153 21.0159812
Class A/1 (Rhodopsin-like
receptors)
3973 6870 LHCGR TACR3 p,0.01 24.7375153 21.0159812
Wikipathways Striated Muscle Contraction 70 7169 ACTC1 TPM2 p,0.01 22.8730277 22.9625465
Peptide GPCRs 3973 6870 LHCGR TACR3 p,0.01 24.7375153 21.0159812
Four genes (ACTC1, TPM2, LHCGR, TACR3) appeared to participate in 8 different pathways.
doi:10.1371/journal.pone.0018135.t003
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was commonly down-regulated among the BC samples. There is
no evidence linking it to BC. In chromosome 13 (Figure 9J), two
genes were commonly down-regulated in the BC samples: RXFP2
and KL. Notably, RXFP2 has been reported to participate in male
reproductive system malignancies and diseases. In a recent report,
it was suggested that this gene is involved in uterine fibroids, where
it was reported to be down-regulated in all diseased samples [63].
RXFP2 is also considered to be a stimulator of genes promoting
proteolysis such as the MMP and TIMP families [64].
Finally, the chromosomes with the majority of commonly up- or
down-regulated DE genes were chromosomes 1 (6 genes), followed
by chromosome 17 (5 genes). In chromosome 1, OTUD7B is a
commonly down-regulated gene which has been reported to
interact and regulate NFkB activity [65,66,67]. NFkB, was
predicted from our analysis as a key factor regulating DE genes
among Grade III tumors. The gene ADAMTSL4, commonly
down-regulated, belongs to the ADAMTS family of proteins with
cell adhesion and angiogenetic properties. It has been reportedly
involved in adult acute leukemia and ovarian cancer, which makes
its involvement in BC a significant finding [68,69]. The gene
ATF3, down-regulated in all samples, encodes for a transcription
factor, and has been previously reported to be involved in BC, and
in particular to be up-regulated in hTERT transformed cells [70].
ACBD3, commonly up-regulated, is a gene that participates in the
maintenance of the Golgi structures of cells. It has been reported
recently that the protein ACBD3 is released in asymmetric cell
division in neural cells [71]. RAB3B, commonly down-regulated,
participates in the regulation of exocytosis. It has been reported to
play a role in rituitary adenomas [72,73]. No reports have been
found for the GPR153 gene.
In chromosome 17, the following genes belonged to the
common expression groups: NCOR1, GFAP, QRICH2, ANAPC11
and PER1. NCOR1, commonly up-regulated, is a transcription
repressor of thyroid-hormone receptors. It has been reported to be
linked to bladder cancer cells. In particular, it has been shown that
over-expression of this gene was linked to the regulation of nuclear
receptors such as PPARgamma and VDR, where PPARgamma
(PPARG) was differentially expressed in our dataset. Interestingly, it
has been reported that NCOR1 over-expression provides a target
for therapies with histone deacetylase inhibitors, such as vorinostat
[74]. There are no reports for the role of GFAP in BC. QRICH2
(glutathione rich 2) is a gene whose functions are unknown. Its
appearance in BC makes an interesting target for further
investigation. ANAPC11, commonly up-regulated, appears to be
a very important factor in the regulation of cell cycle progression,
whereas its aberrant expression is linked to tumor progression
[75,76]. The presence of this gene in our samples implies that it
Figure 19. GO terms annotation of the common gene set. Three functions could be outlined a) circulatory functions, b) reproductive organ
development and catecholamine metabolism.
doi:10.1371/journal.pone.0018135.g019
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could also imply that its over-expression is a marker of good
prognosis since all patients responded positively to therapy. PER1,
commonly down-regulated, is a very important gene since it is the
primary circadian pacemaker of the brain. Furthermore, it has
been reported to suppress tumor cell proliferation [77] and its
expression varies with aggressiveness due to polymorphisms of the
gene in prostate cancers [78].
Cross-Platform Comparisons. In the case of cross-
platform comparisons, inactivated genes were predicted. Also,
three genes appeared to be activated i.e. over-expressed: CDC20,
TM9SF1 and HCCS. Special interest was given to HCCS.I ti s
located on the X chromosome and to date, there are no reports
linking it to bladder cancer. Yet, it is one of the few activated genes
that was common to all samples. HCCS is a mitochondrial gene,
which means that it is inherited from the mother alone.
Considering that mitochondrial dysfunction is closely related to
cancer progression [79,80], HCCS may play an interesting role in
bladder cancer.
Pathway Analysis
The CodeLink Case. In search for common pathways, when
the CodeLink dataset was analyzed alone, the urinary bladder cancer
pathway was identified as the first and most prevalent one.
Cross-Platform Comparisons. Since the Cross-Platform
Comparisons identified 17 common genes among all of the tumor
samples, the following question arose: how can we identify the
most significant among them? Considering the multi-dimensional
nature of cancer biology, there are more than one factor or gene
that affects tumor behavior. This phenomenon is encountered in
many aspects of cancer biology, from tumorigenesis to drug
resistance and prognosis. Therefore, we hypothesized that the
most significant genes, if any, should participate simultaneously in
a variety of functions/pathways. The key aspect here is that all of
them are common to all of the samples studied in the present
work. Therefore, common pathway participation should also be
expected to exist among samples. Hence, mapping those genes on
known pathways revealed four genes that participate in 8 different
pathways. The following were the most prevalent genes in
pathway participation, and were found to be down-regulated in
BC: ACTC1, TPM2, LHCGR and TACR3, To date, there are no
reports linking them to BC. However, their inactivation in a
variety of known pathways implies that they have a putative role.
Interestingly, LHCGR, ACTC1 and TPM2 comprise the top-3
down-regulated genes compared to the control samples.
GO analysis
The CodeLink Case. GO analysis and functional gene
annotations provided further insight into the expression profile
of the common genes. We searched within five main categories of
GO annotations: cell death, cell growth, metabolism, development
and RNA processing (Figure 10). First of all, we tested the genes
for their functions and searched among those genes for the ones
that manifested common expression patterns. Second, we
analyzed common families of genes between the samples and
tumor groups for significant functions.
Three cell death-related genes were commonly regulated in all
samples: PUF60, ADAMTSL4 and BCL2L1. PUF60 was recently
reported as a novel factor of tumor progression [81]. This is in
agreement with the present study, since it was also up-regulated in
the BC samples. ADAMTSL4 was described in the previous
section. Finally, BCL2L1, commonly down-regulated, is a
mitochondrial gene expressed by the nucleus. It is localized in
the mitochondrial membrane and facilitates the release of
cytochrome C which is considered to be an effector of apoptosis.
Consistent down-regulation of the BCL2L1 gene indicates that it
could be considered for use as a prognostic or therapeutic marker
in BC. The second category included developmental genes, i.e.
genes known to participate in embryonic development
(Figure 10D). TNFRSF17 belongs to the Tumor Necrosis Family
receptors. One of its functions is the activation of NFkB factor and
it also participates in B-cell maturation. Also, it participates in
embryonic B-cell development [82]. KL (klotho) encodes a type-I
membrane protein that is related to beta-glucosidases. In a recent
report, KL promoted apoptosis and growth inhibition in lung
cancer cells [83]. This implies a similar function for BC.
Regarding the metabolism-related genes we outlined: NPC1L1,
NCOA5 and ELOVL3. NPC1L1 codes for a protein that takes up
free cholesterol into cells through vesicular endocytosis and also
participates in lipid metabolism. It has been indirectly linked to
carcinogenesis through inhibition of its function [84]. NCOA5 is a
Figure 20. One-way ANOVA showed significant differences
between samples 4A and 29A in up-regulated genes (A) while
there were no significant differences in down-regulated genes
(B) as both groups were mapped on chromosomes.
doi:10.1371/journal.pone.0018135.g020
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metabolism. It has been reported to regulate c-MYC expression
as a downstream target of TIP30 [85]. Finally, ELOVVL3
participates in fatty acid chain elongation and formation of
neutral lipids. It has been reported that this gene is controlled by
steroid hormones in mouse models [86]. Lipid metabolism is
involved indirectly with BC and in particular through the PPARG
gene [87]. As another example we could refer to the metabolism
of arachidonic acid as an important tumor promotion factor [88].
The link between lipid metabolism and BC warrants further
investigation.
Finally, analysis of all DE genes as well as the groups with
common expression revealed the prevalence of transport and
binding genes, and RNA processing genes (Figure 10E–G). In
particular, prevalence of transport and binding genes was noted
in the common down-regulated DE genes; the prevalence of
RNA metabolism and processing genes in the up-regulated DE
genes; as well as the prevalence of genes responsible for cell
communication and signal transduction in the DE genes that
were down-regulated in T1-Grade III tumors and up-regulated in
T2/T3-Grade III tumors. The RNA processing genes included
NCOR1 (as previously discussed), ZNF135 and ATF3. ZNF135 is a
zinc finger protein for which not much is known. It was
consistently down-regulated in all samples, which denotes a
possible role in BC.
Cross-Platform Comparisons. The GO analysis results
were different in the case of Cross-Platform Comparisons. A total of 17
genes with several functions, apart from cell growth or cell death,
was obtained. Thus far, there are no reports connecting catechol,
diol, phenol or catecholamine metabolism with bladder cancer.
Moreover, it was interesting to attribute developmental functions
to the identified common genes.
Conclusions
In the present work we employed microarray analyses in order
to identify the common gene expression profile in bladder cancer.
Previous gene expression studies have focused on identifying
differences between tumor samples of the same type. Using a
reverse engineering approach, we searched for common expres-
sion profiles among tumor samples. Through this investigation we
were able to identify several important factors that warrant
further investigation both as prognostic markers and as
therapeutic targets. Such approaches may provide a better
insight into tumorigenesis and tumor progression. The present
findings reveal that tumors probably possess common character-
istics. This type of gene expression analysis will provide further
insights in the identification of universal tumor markers and will
therefore aid in the development of more effective therapeutic
approaches.
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